The treatment for life-threatening allergies has been the flagship branded drug of Mylan, Teva's generic pharmaceutical rival.

EpiPen has been the flagship branded drug of Mylan, Teva's generic pharmaceutical rival. Mylan acquired the drug from Merck KGaA in 2007. Teva has had a protracted wait for FDA approval for generic EpiPen after its 2016 application was rejected on the grounds that a generic version could only be launched in 2017. In the end approval was only awarded this year. EpiPen has had a controversial history with serious complaints two years ago about price hikes and a $465 million settlement in a compromise agreement with the government Medicaid insurance program over incorrect classification.